We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.70 | 4.38% | 40.50 | 39.70 | 40.50 | 40.00 | 39.00 | 39.60 | 359,491 | 16:35:16 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -5.85M | -0.0194 | -20.62 | 120.28M |
TIDMFUM
RNS Number : 9309P
Futura Medical PLC
31 May 2018
31 May 2018
Futura Medical plc
("Futura" or "the Company")
Total Voting Rights
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology announces that, for the purposes of the FCA's Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 121,006,002 Ordinary Shares.
Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is 121,006,002 and this figure may therefore be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
For further information please contact: For media enquiries please contact:
Futura Medical plc Buchanan Communications Limited Angela Hildreth, FD/COO Mark Court / Stephanie Watson / + 44 (0) 1483 685 670 Sophie Wills angela.hildreth@futuramedical.com + 44 (0) 20 7466 5000 www.futuramedical.com Nominated Adviser N+1 Singer Aubrey Powell / Liz Yong +44 (0) 20 7496 3000
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
TVRMMGFKNMLGRZM
(END) Dow Jones Newswires
May 31, 2018 13:20 ET (17:20 GMT)
1 Year Futura Medical Chart |
1 Month Futura Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions